Wolverine Blend is a dual-peptide research formulation of BPC-157 and Thymosin Beta 4 (TB-500), combining the two most-studied tissue-repair peptides with complementary preclinical mechanisms.

Recovery Peptides

Wolverine Blend (BPC-157 / TB-500)

The Wolverine Blend combines BPC-157 and Thymosin Beta 4 (TB-500) in a single research formulation — the two most-studied tissue-repair peptides in the preclinical literature, combined because their mechanisms are complementary rather than redundant. BPC-157 is a pentadecapeptide (15 amino acids) that has been extensively investigated in preclinical models for gut-barrier protection, tendon and ligament repair, and angiogenesis through the NO signaling pathway. TB-500 is a 43-amino-acid actin-sequestering peptide studied for cardiac repair, systemic wound healing, cell migration promotion, and anti-inflammatory mechanisms. The combination has a research rationale grounded in mechanistic complementarity: BPC-157 operates through localized angiogenesis and NO-system interaction in connective tissue models; TB-500 operates through actin regulation and systemic cell migration promotion across cardiac, dermal, and musculoskeletal tissue types. Together, they represent the most commonly studied peptide pairing in the recovery research literature. Researchers studying musculoskeletal recovery, connective tissue repair, post-injury tissue remodeling, or combined repair mechanisms use the Wolverine Blend as a convenient single-vial formulation that eliminates the need to manage two separate compounds across a study protocol. This listing is for laboratory and preclinical research purposes only. Not for human or veterinary use.

Product Information

Shipping & Returns

Select Format
From $2,500.00
Wolverine Blend (BPC-157 / TB-500)-
$2,500.00

Product definition

What is Wolverine Blend (BPC-157 / TB-500)?

Wolverine Blend is a dual-peptide research formulation of BPC-157 and Thymosin Beta 4 (TB-500), combining the two most-studied tissue-repair peptides with complementary preclinical mechanisms.

The Wolverine Blend is a combined research formulation containing BPC-157 (Body Protection Compound 157) and Thymosin Beta 4 (TB-500). Both compounds have extensive independent preclinical research profiles, and the combination has become one of the most commonly studied peptide pairings in the tissue-repair research literature. BPC-157 is a 15-amino-acid pentadecapeptide derived from gastric protein, studied for tendon healing, gut-barrier protection, angiogenesis, and neuroprotective effects in animal models. TB-500 is a 43-amino-acid actin-binding peptide studied for cardiac muscle repair, wound closure acceleration, hair follicle activation, and systemic anti-inflammatory effects. Their proposed mechanisms are distinct and complementary, targeting different aspects of the tissue repair cascade.

Research context

How is Wolverine Blend (BPC-157 / TB-500) described in the research literature?

BPC-157 in the blend operates through NO-system interaction and localized angiogenesis promotion in connective tissue models. TB-500 complements this through actin-G sequestration, promoting cell migration and systemic tissue repair across cardiac, dermal, and musculoskeletal injury models. The combination targets different nodes of the tissue repair cascade simultaneously.

Compound profile

Key facts about Wolverine Blend (BPC-157 / TB-500)

Components
BPC-157 + Thymosin Beta 4 (TB-500)
BPC-157 class
Pentadecapeptide, 15 amino acids
TB-500 class
Actin-sequestering peptide, 43 amino acids
Research category
Combined tissue repair, musculoskeletal, cardiac
Format
Lyophilized blend (single vial)
Storage
Lyophilized: −20°C. Reconstituted: 2–8°C, use within 30 days

Research areas

What research areas is Wolverine Blend (BPC-157 / TB-500) associated with?

  • Combines BPC-157's gut and tendon repair research with TB-500's cardiac and systemic repair profile
  • Mechanistically complementary — targets both localized connective tissue and systemic cell migration repair pathways
  • Most commonly studied peptide pairing in preclinical tissue-repair research literature
  • Convenient single-vial formulation for research protocols requiring both compounds
  • Covers both NO-system angiogenesis research (BPC-157) and actin-regulation repair research (TB-500)
  • Supported by independent preclinical data for both component peptides across multiple tissue types

Research audience

Who researches Wolverine Blend (BPC-157 / TB-500)?

The Wolverine Blend is used by researchers in musculoskeletal repair, sports medicine preclinical work, post-injury tissue remodeling research, and cardiac recovery studies. It is favored when research protocols call for both compounds and single-vial convenience reduces preparation complexity.

Preclinical research overview

What does the preclinical literature say about Wolverine Blend (BPC-157 / TB-500)?

The combination of BPC-157 and TB-500 emerged as a research pairing because researchers studying repair mechanisms noted that the two peptides target distinct but parallel nodes of the tissue repair process. BPC-157 literature documents activity primarily in localized injury models — Achilles tendon, gastric ulceration, anastomotic repair — through proposed NO-system and VEGF pathway interactions. TB-500 literature documents activity primarily in systemic models — myocardial infarction, cutaneous wounds, hair regrowth — through actin regulation and cell migration mechanisms. In practical research terms, the Wolverine Blend (5 mg BPC-157 + 5 mg TB-500 or 10 mg + 10 mg) is used when investigators want to study both mechanisms without managing two separate lyophilized compounds. The formulation is particularly common in orthopedic and sports science preclinical research where both localized connective tissue repair and systemic healing mechanisms are of interest.

Common questions

Frequently asked about Wolverine Blend (BPC-157 / TB-500)

Why combine BPC-157 and TB-500 rather than use each separately?

The combination is used when research protocols require coverage of both localized connective tissue repair mechanisms (BPC-157's primary research area) and systemic cell-migration and cardiac repair mechanisms (TB-500's primary research area). Using a pre-blended formulation reduces preparation complexity in multi-compound protocols.

Does combining them affect the activity of either compound?

No studies to date indicate negative interaction between BPC-157 and TB-500 in combination. The mechanisms are proposed to be distinct and non-competing. Some animal studies have specifically used the combination to examine synergistic or additive effects in injury models.

Which blend ratio should researchers select?

Peptific offers two ratios: 5 mg BPC-157 / 5 mg TB-500 and 10 mg BPC-157 / 10 mg TB-500. Ratio selection depends on the specific research protocol and study duration requirements. The higher dose formulation is generally used in longer-duration or larger animal preclinical studies.

Related products

You might also want to check out these products.

Research Use Only

Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.

Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.

By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy